Top entities: Cosmos Health, Abbott Laboratories, Pharmex S.A..

What category does this event fall under?

Business — classified as contract manufacturing agreement.

What is the sentiment of coverage?

Aggregate sentiment score: 60 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business contract manufacturing agreement

Cosmos Health signs Pharmex manufacturing deal

Q: When did this event occur?

First reported Jun 17, 2026; last updated Jun 17, 2026.

Q: What is the market impact?

General. The agreement is expected to positively impact Cosmos Health by strengthening its recurring revenue and increasing the utilization of its manufacturing capacity.

Analysis based on 7 articles · First reported Jun 17, 2026 · Last updated Jun 17, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The agreement is expected to positively impact Cosmos Health by strengthening its recurring revenue and increasing the utilization of its manufacturing capacity. For Pharmex S.A., it ensures a stable supply of key dermatological products for its global distribution network.

Pharmaceuticals

Event Summary

Cosmos Health Inc., through its wholly owned subsidiary Abbott Laboratories, has entered into a five-year contract manufacturing agreement with Pharmex S.A. Abbott Laboratories will manufacture three dermatological products, including BETAFUSIN®, BOTAFEX®, and BUDESODERM®, totaling approximately 2.86 million units over the term. This agreement reinforces Cosmos Health's role as a contract manufacturer and is expected to enhance recurring revenue and facility utilization. Pharmex S.A., a Greek pharmaceutical company, will benefit from the manufacturing capabilities of Abbott Laboratories to support its product availability in over 20 countries.

Entities Involved

stock

Cosmos Health

Cosmos Health, through its subsidiary Abbott Laboratories, entered into a five-year contract manufacturing agreement with Pharmex S.A., which is expected to strengthen its recurring revenue and maximize the utilization of its EU-licensed facilities.

Importance 100.0 Sentiment 70.0

stock

Abbott Laboratories

Abbott Laboratories, a wholly owned subsidiary of Cosmos Health, will manufacture 2.86 million units of three pharmaceutical products for Pharmex S.A. over five years, leveraging its EU-GMP-licensed facility.

Importance 90.0 Sentiment 70.0

priv

Pharmex S.A.

Pharmex S.A. secured a five-year contract manufacturing agreement with Abbott Laboratories for the production of three dermatological products, ensuring a stable supply for its global distribution.

Importance 80.0 Sentiment 60.0

Relationships

Cosmos Health related ↔ Abbott Laboratories

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard